Subject Index

ACC, see Adenoid cystic carcinoma
ADAM17, radiotherapy response 30
Adenoid cystic carcinoma (ACC), particle therapy 92, 93
ATM, radiogenomics 110
Avastin 34

BRCA, radiogenomics 110

Carbon ion radiotherapy, see Particle therapy
Cardiac disease, radiation induction 114, 115
Cataract, radiation induction 113
Cell proliferation
causes 20
lung cancer 44
positron emission tomography 20, 21
radioresistance 20
Cervical cancer, particle therapy 97, 98
Charged particle therapy, see Particle therapy
Chondrosarcoma, particle therapy 91
Clinical target volume (CTV)
lung cancer 43
treatment planning 49, 62, 63
Cognitive dysfunction, radiation induction 113, 114
Computed tomography (CT)
lung cancer
clinical target volume 43
gross tumor volume 42, 43
heterogeneity 44, 45
response assessment 45
radiotherapy response biomarkers 12, 13
treatment planning 49, 50, 60, 61
Craniopharyngioma, particle therapy 98
CT, see Computed tomography
CTLA-4, therapeutic targeting 2, 4

CTV, see Clinical target volume
Cu-ATSM, hypoxia imaging 19

DC101 33, 34
Dose prescription, see Treatment planning

Ependymoma, particle therapy 98
Esophagus cancer, particle therapy 96
Eovfofsamide (TH-302) 33

Fluorothymidine proliferation imaging 20, 21

Glioma, particle therapy 90
Gross tumor volume (GTV)
lung cancer 42, 43
treatment planning 49
GTV, see Gross tumor volume

HCC, see Hepatocellular carcinoma
Head and neck cancer, particle therapy 92
Hepatocellular carcinoma (HCC)
particle therapy 94, 95
radiation induction 113

Hypoxia
causes 16
imaging
magnetic resonance imaging 19
overview 14, 15
positron emission tomography 17–19
particle therapy considerations 109, 110
radioresistance of hypoxic tumors 15, 16
therapeutic targeting 31–33
tumor microenvironment 26
tumor sensitization 16, 17

IL-2, see Interleukin-2
Immunotherapy
  cancer vaccines 2
  checkpoint inhibition 2
  historical perspective 1
  immunocytokines 3
  radiation therapy combination
    cancer vaccine 4
    clinical trials 6, 7
    immune checkpoint inhibition 4
    rationale 3, 4
    T cell effects 4, 5
    tumor microenvironment and cytokine-based therapies 5, 6
    T cell targeting 2, 3
    tumor biology 1, 2
  Interleukin-2 (IL-2), immunotherapy 3
  Ion beam therapy, see Particle therapy
  Ipilimumab, development 2

Lung cancer
  cell proliferation 44
  clinical target volume 43
  gross tumor volume 42, 43
  heterogeneity 44
  hypoxia 43, 44
  particle therapy for non-small-cell lung cancer
    advanced 93, 94
    early 93
  response assessment 45
  stereotactic body radiotherapy
    high-risk situations 74–76
    indications 76
    non-small-cell lung cancer 67, 69–74
    oligo-metastatic cancer 77–81
    oligo-progressive cancer 81–83

Magnetic resonance imaging (MRI)
  hypoxia imaging 19, 20
  radiotherapy response biomarkers 13
  treatment planning 50, 61, 62
  MCT1 36
  Medulloblastoma, particle therapy 98
  Melanoma, particle therapy 92
  Meningioma, particle therapy 90
  Microenvironment, see Tumor microenvironment
  MRI, see Magnetic resonance imaging

Nitroimidazole
  hypoxia imaging 17–19

radiosensitization 31–33

Non-small-cell lung cancer, see Lung cancer

Pancreatic cancer, particle therapy 95, 96

Particle therapy
  cervical cancer 97, 98
  chemotherapy combination 115, 116
  DNA damage and repair 107–109
  esophagus cancer 96
  glioma 90
  head and neck cancer 92
  hepatocellular carcinoma 94, 95
  hypoxia considerations 109, 110
  immune response 115, 116
  late adverse effects 111–115
  lung cancer, non-small-cell lung cancer
    advanced 93, 94
    early 93
  meningioma 90
  mouse models
    carbon ion radiotherapy optimization 124, 125
    laser-driven particle acceleration studies 127, 128
    overview 122–124
    spatial fractionation studies 125–127
    overview 105–107
  pancreatic cancer 95, 96
  pediatric cancer 98, 99
  prostate cancer 96, 97
  radiogenomics 110, 111
  rectal cancer 96
  sarcoma 91, 92
  skull base cancer 91
  stereotactic body radiotherapy and hypofractionation 116, 117
  PD-1, therapeutic targeting 2, 4
  PET, see Positron emission tomography
  Planned target volume (PTV), treatment planning 49, 50, 62, 63
  Positron emission tomography (PET)
    hypoxia imaging 17–19
    lung cancer
      cell proliferation 44
      clinical target volume 43
      gross tumor volume 42, 43
      heterogeneity 44
      hypoxia 43, 44
      response assessment 45
proliferation imaging 20, 21
radiotherapy response biomarkers 13, 14
treatment planning 50
Proliferation see Cell proliferation
Prostate cancer, particle therapy 96, 97
Proton radiotherapy, see Particle therapy
PTV, see Planned target volume

Rectal cancer, particle therapy 96
Rhabdomyosarcoma, particle therapy 98, 99

Sarcoma, particle therapy 91, 92
SBRT, see Stereotactic body radiotherapy
Skull base cancer, particle therapy 91
Stereotactic body radiotherapy (SBRT)  
  historical perspective 67, 68
  hypofractionation 116, 117
  lung cancer  
    high-risk situations 74–76
    indications 76
    non-small-cell lung cancer 67, 69–74
    oligo-metastatic cancer 77–81
    oligo-progressive cancer 81–83
  principles 68, 69

Temozolomide, particle therapy combination 115
TGF-β, see Transforming growth factor-β
TH-302, see Evovfofsamide
TME, see Tumor microenvironment
TNP-470 33
Transforming growth factor-β (TGF-β), therapeutic targeting 3

Treatment planning  
  dose prescription  
    dose painting 56–58
    functional organ sparing 58–60
    optimization 55, 56
  overview 55

geometric uncertainties  
  patient motion models 60, 61
  real-time planning and quality assurance 61, 62
  robust optimization 62, 63
  navigation 51, 52
  optimization 51, 53, 54
  plan quality prediction 54, 55
  standardization 50, 51
  trends 49, 50

Tumor microenvironment (TME)  
  extracellular matrix 27
  hypoxia 26
  immunotherapy combination with radiation therapy 5, 6
  overview 25, 26
  stromal cells 27
  therapeutic targeting  
    fibrotic compartment 36, 37
    hypoxia 31–33
    metabolism 36
    tumor cell compartment 30, 31
    vasculature 33–36
  treatment resistance  
    cell-driven treatment resistance 29
    fibrotic compartment-linked treatment resistance 29, 30
    immune-driven treatment resistance 30
    overview 27, 28
    vascular-related treatment resistance 28, 29
    vasculature 26, 27

Vascular endothelial growth factor (VEGF)  
  radiotherapy response 29
  therapeutic targeting 30, 33–35
  VEGF, see Vascular endothelial growth factor